Edgewise Therapeutics Advances Sevasemten Phase 3 Trial for Duchenne Muscular Dystrophy with Enhanced Statistical Power
核心洞察
Edgewise Therapeutics has expanded enrollment in its pivotal GRAND CANYON Phase 3 trial of sevasemten from 120 to 175 patients, increasing statistical power to approximately 98% to detect a 1.8-point improvement in North Star Ambulatory Assessment.
The company remains on track for Phase 3 readout in Q4 2024 and targets potential regulatory approval by end-Q4 2027, with first full-year revenue projected for 2028 if results are positive.
For its hypertrophic cardiomyopathy (搜索) program, Edgewise has revised EDG-7500 screening protocols to address earlier atrial fibrillation (搜索) concerns and plans to disclose Part D results covering both obstructive and non-obstructive HCM before initiating Phase 3 in Q4.
Edgewise Therapeutics has significantly strengthened its pivotal Phase 3 trial of sevasemten for Duchenne muscular dystrophy (搜索) by expanding enrollment from 120 to 175 patients, positioning the GRAND CANYON study with approximately 98% statistical power to detect a clinically meaningful 1.8-point improvement in the North Star Ambulatory Assessment.
The enhanced enrollment provides substantial statistical robustness for the pivotal readout scheduled for Q4 2024. If positive results emerge, Edgewise targets potential regulatory approval by the end of Q4 2027, with first full-year revenue projected for 2028.
Addressing Safety Concerns in HCM Program
To address earlier atrial fibrillation (搜索) concerns that emerged in its hypertrophic cardiomyopathy (搜索) program, Edgewise has implemented comprehensive protocol revisions for EDG-7500 screening. The updated approach includes core-lab echocardiograms, 180-day atrial fibrillation look-back periods, and exclusion of higher-risk valve patients.
The company has deployed continuous patch monitoring to enhance safety surveillance, reporting no atrial fibrillation (搜索) burden and no correlation between plasma concentration and left ventricular ejection fraction. These safety measures represent a proactive response to earlier cardiovascular concerns that could have impacted the program's advancement.
HCM Program Progression
Edgewise plans to disclose Part D results covering both obstructive and non-obstructive hypertrophic cardiomyopathy (搜索) before initiating Phase 3 trials in Q4. This data release will provide critical insights into the therapeutic potential across the broader HCM patient population and inform the design of the upcoming pivotal studies.
The comprehensive approach to both the Duchenne muscular dystrophy (搜索) and hypertrophic cardiomyopathy (搜索) programs demonstrates Edgewise's commitment to addressing regulatory and safety considerations while maintaining development timelines. The substantial increase in statistical power for the GRAND CANYON trial, combined with the refined safety protocols for the HCM program, positions the company for potential regulatory success across both therapeutic areas.